The trial to assess chelation therapy 2 (TACT2): Rationale and design.

Journal Article (Journal Article;Multicenter Study)

BACKGROUND: Intravenous edetate disodium-based infusions reduced cardiovascular events in a prior clinical trial. The Trial to Assess Chelation Therapy 2 (TACT2) will replicate the initial study design. METHODS: TACT2 is an NIH-sponsored, randomized, 2x2 factorial, double masked, placebo-controlled, multicenter clinical trial testing 40 weekly infusions of a multi-component edetate disodium (disodium ethylenediamine tetra-acetic acid, or Na2EDTA)-based chelation solution and twice daily oral, high-dose multivitamin and mineral supplements in patients with diabetes and a prior myocardial infarction (MI). TACT2 completed enrollment of 1000 subjects in December 2020, and infusions in December 2021. Subjects are followed for 2.5 to 5 years. The primary endpoint is time to first occurrence of all-cause mortality, MI, stroke, coronary revascularization, or hospitalization for unstable angina. The trial has >;85% power to detect a 30% relative reduction in the primary endpoint. TACT2 also includes a Trace Metals and Biorepository Core Lab, to test whether benefits of treatment, if present, are due to chelation of lead and cadmium from patients. Design features of TACT2 were chosen to replicate selected features of the first TACT, which demonstrated a significant reduction in cardiovascular outcomes in the EDTA chelation arm compared with placebo among patients with a prior MI, with the largest effect in patients with diabetes. RESULTS: Results are expected in 2024. CONCLUSION: TACT2 may provide definitive evidence of the benefit of edetate disodiumbased chelation on cardiovascular outcomes, as well as the clinical importance of longitudinal changes in toxic metal levels of participants.

Full Text

Duke Authors

Cited Authors

  • Lamas, GA; Anstrom, KJ; Navas-Acien, A; Boineau, R; Kim, H; Rosenberg, Y; Stylianou, M; Jones, TLZ; Joubert, BR; Santella, RM; Escolar, E; Aude, YW; Fonseca, V; Elliott, T; Lewis, EF; Farkouh, ME; Nathan, DM; Mon, AC; Gosnell, L; Newman, JD; Mark, DB; TACT2 Investigators,

Published Date

  • October 2022

Published In

Volume / Issue

  • 252 /

Start / End Page

  • 1 - 11

PubMed ID

  • 35598636

Pubmed Central ID

  • PMC9434822

Electronic International Standard Serial Number (EISSN)

  • 1097-6744

Digital Object Identifier (DOI)

  • 10.1016/j.ahj.2022.05.013


  • eng

Conference Location

  • United States